Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the ...

New research across a broad range of hematologic malignancies to be featured during the meeting, including presentations for investigational assets zilovertamab vedotin and nemtabrutinib RAHWAY, N.J.- ...

Cilta-cel plus daratumumab shows significant efficacy in multiple myeloma, offering prolonged progression-free survival and sustained MRD negativity, especially in high-risk patients. Acalabrutinib ...